Evaluation of [18F]PI-2620, a second-generation selective tau tracer, for assessing four-repeat tauopathies. Issue 4 (24th August 2021)

• Record Type: Journal Article
• Authors: Tezuka, Toshiki; Takahata, Keisuke; Seki, Morinobu; Tabuchi, Hajime; Momota, Yuki; Shiraiwa, Mika; Suzuki, Natsumi; Morimoto, Ayaka; Nakahara, Tadaki; Iwabuchi, Yu; Miura, Eisuke; Yamamoto, Yasuharu; Sano, Yasunori; Funaki, Kei; Yamagata, Bun; Ueda, Ryo; Yoshizaki, Takahito; Mashima, Kyoko; Shibata, Mamoru; Oyama, Munenori; Okada, Kensuke; Kubota, Masahito; Okita, Hajime; Takao, Masaki; Jinzaki, Masahiro; Nakahara, Jin; Mimura, Masaru; Ito, Daisuke
• Is Part Of: Brain communications. Volume 3:Issue 4(2021)
• Publication Date: 2021-08-24
• Subjects: Tau imaging -- Alzheimer's disease -- tauopathy -- progressive supranuclear palsy -- corticobasal degeneration; 616
• DOI: 10.1093/braincomms/fcab190
• Languages: English
• ISSNs: 2632-1297

Abstract

Abstract: Tau aggregates represent a key pathologic feature of Alzheimer's disease and other neurodegenerative diseases. Recently, PET probes have been developed for in vivo detection of tau accumulation; however, they are limited because of off-target binding and a reduced ability to detect tau in non-Alzheimer's disease tauopathies. The novel tau PET tracer, [ 18 F]PI-2620, has a high binding affinity and specificity for aggregated tau; therefore, it was hypothesized to have desirable properties for the visualization of tau accumulation in Alzheimer's disease and non-Alzheimer's disease tauopathies. To assess the ability of [ 18 F]PI-2620 to detect regional tau burden in non-Alzheimer's disease tauopathies compared with Alzheimer's disease, patients with progressive supranuclear palsy ( n = 3), corticobasal syndrome ( n = 2), corticobasal degeneration ( n = 1) or Alzheimer's disease ( n = 8), and healthy controls ( n = 7) were recruited. All participants underwent MRI, amyloid β assessment and [ 18 F]PI-2620 PET (Image acquisition at 60–90 min post-injection). Cortical and subcortical tau accumulations were assessed by calculating standardized uptake value ratios using [ 18 F]PI-2620 PET. For pathologic validation, tau pathology was assessed using tau immunohistochemistry and compared with [ 18 F]PI-2620 retention in an autopsied case of corticobasal degeneration. In Alzheimer's disease, focal retention of [ 18 F]PI-2620 was evident in the temporal and parietal lobes, precuneus, and cingulate cortex. Standardized uptake value ratio analyses revealed that patients with non-Alzheimer's disease tauopathies had elevated [ 18 F]PI-2620 uptake only in the globus pallidus, as compared to patients with Alzheimer's disease, but not healthy controls. A head-to-head comparison of [ 18 F]PI-2620 and [ 18 F]PM-PBB3, another tau PET probe for possibly visualizing the four-repeat tau pathogenesis in non-Alzheimer's disease, revealed different retention patterns in one subject with progressive supranuclear palsy. Imaging-pathology correlation analysis of the autopsied patient with corticobasal degeneration revealed no significant correlation between [ 18 F]PI-2620 retention in vivo . High [ 18 F]PI-2620 uptake at 60–90 min post-injection in the globus pallidus may be a sign of neurodegeneration in four-repeat tauopathy, but not necessarily practical for diagnosis of non-Alzheimer's disease tauopathies. Collectively, this tracer is a promising tool to detect Alzheimer's disease-tau aggregation. However, late acquisition PET images of [ 18 F]PI-2620 may have limited utility for reliable detection of four-repeat tauopathy because of lack of correlation between post-mortem tau pathology and different retention pattern than the non-Alzheimer's disease-detectable tau radiotracer, [ 18 F]PM-PBB3. A recent study reported that [ 18 F]PI-2620 tracer kinetics curves in four-repeat tauopathies peak earlier (within 30 min) than Alzheimer's disease; therefore, further studies are needed to determine appropriate PET acquisition times that depend on the respective interest regions and diseases. Abstract : This study reports that the novel tau-tracer, [ 18 F]PI-2620 (late time frame), is a promising tool for detecting Alzheimer's disease-tau deposits. However, this may have limited utility for the detection of four-repeat tau-pathology due to the lack of correlation with post-mortem pathology and different distribution with the non-Alzheimer's disease tau-tracer, [ 18 F]PM-PBB3. Graphical Abstract: